FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market. Key Highlights Launched Holistic Health Reset Program with First Responders in NevadaIn August 2025, Avalon, together with Saga Health and Specialty ...

Core Points - Oracle Corporation has elected Stephen Rusckowski to its Board of Directors, increasing the board size to 14 members, effective November 18, 2025 [1][4] - Rusckowski has extensive experience in healthcare and technology, having served as CEO of Quest Diagnostics and Philips Healthcare, which is expected to provide valuable insights for Oracle Health [2][3] - The board members serve one-year terms, with the next election scheduled for November 2026 [4] Company Background - Oracle offers integrated applications and secure, autonomous infrastructure in the Oracle Cloud, positioning itself as a leader in cloud computing [5]

Core Viewpoint - Quest Diagnostics has shown a positive performance in its stock price, outperforming the S&P 500, but there are questions about whether this trend will continue leading up to the next earnings release [1] Financial Performance - Quest Diagnostics reported Q3 2025 adjusted earnings per share (EPS) of $2.60, exceeding the Zacks Consensus Estimate by 3.59% and up 13% from the previous year [2] - The company's GAAP earnings were $2.16 per share, reflecting an 8.5% increase year-over-year [3] - Revenues for Q3 rose 15.2% year-over-year to $2.82 billion, surpassing the Zacks Consensus Estimate by 3.45% [4] - Diagnostic Information Services revenues increased by 13.5% year-over-year to $2.76 billion, exceeding projections [4] - Volumes measured by requisitions were up 12.5% year-over-year, with revenue per requisition increasing by 0.8% [5] Margin Analysis - The cost of services in Q3 was $1.87 billion, up 11.3% year-over-year, while gross profit rose 17% to $949 million [6] - The gross margin improved to 33.7%, an increase of 110 basis points [6] - SG&A expenses totaled $501 million, up 11.8% from the previous year, with an adjusted operating margin of 15.9%, representing a 132-basis point expansion [6] Financial Position - At the end of Q3 2025, Quest Diagnostics had cash and cash equivalents of $432 million, up from $319 million at the end of Q2 [7] - The cumulative net cash provided by operating activities was $1.42 billion, compared to $858 million a year ago [7] - The company has a five-year annualized dividend growth rate of 7.21% [7] Guidance - Quest Diagnostics updated its full-year 2025 revenue outlook to a range of $10.96-$11.00 billion, indicating a year-over-year increase of 11-11.4% [8] - Adjusted EPS is expected to be in the range of $9.76-$9.84, up from previous estimates [8] Market Sentiment - There has been a downward trend in estimates revision for the stock over the past month [10] - Quest Diagnostics holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [12] - The company has a Growth Score of B, a Momentum Score of F, and a Value Score of B, placing it in the top 40% for value investors [11]

Core Viewpoint - bioAffinity Technologies, Inc. (BIAF) has experienced a significant decline in stock value following its third-quarter 2025 results, with shares dropping 21.8% since the earnings release, compared to a 2.2% loss in the S&P 500 Index during the same period [1] Financial Performance - In Q3 2025, bioAffinity reported total revenues of $1.4 million, a decrease of 38.5% from $2.4 million in the same quarter last year, due to a strategic exit from unprofitable pathology services and a focus on CyPath Lung commercialization [2] - CyPath Lung testing revenue increased by 122% year-over-year, driven by higher case volumes and increased physician adoption, particularly within Veterans Administration (VA) medical centers [2] - Operating expenses fell by 13.5% to $3.7 million from $4.3 million, primarily due to lower laboratory-related costs, but the net loss widened to $5.1 million from $2 million a year ago, largely due to non-cash expenses related to warrant revaluations [3] - Loss per share slightly narrowed to $4.74 from $4.84 [3] Operational Metrics - Direct costs decreased by 34.6% year-over-year to $0.9 million from $1.4 million, reflecting efficiency initiatives [4] - Selling, general, and administrative expenses decreased by 6.6%, while depreciation and amortization expenses dropped by 25.1% [4] - Research and development (R&D) spending rose by 20.4%, and clinical development costs increased by 52.9% due to expanded preclinical and clinical work [4] Growth and Adoption - Test volumes for CyPath Lung increased by 97% in the first nine months of 2025 compared to the prior year, with a record quarterly sales level in Q3 2025, climbing 92% from the previous quarter [5] - Management emphasized the importance of marketing initiatives targeting the VA health system, which have shown positive traction [7] Balance Sheet and Cash Position - Cash and equivalents improved significantly to $7.7 million from $1.1 million at year-end 2024, supported by $10.4 million in gross proceeds from equity transactions during the quarter [6] Strategic Focus and Future Plans - Management outlined strategic objectives for 2025, including expanding the sales team, engaging with major VA medical centers, and increasing marketing efforts [11] - The company is advancing companion diagnostic candidates for asthma and chronic obstructive pulmonary disease (COPD), targeting an estimated $26 billion global market [12] Governance and Intellectual Property - bioAffinity strengthened its governance with new board appointments and regained full Nasdaq Capital Market compliance [13] - The company added another U.S. patent protecting its proprietary algorithm used in CyPath Lung, marking its second consecutive quarter of patent portfolio expansion [13]

Business Performance - Lucid Diagnostics achieved a record quarterly revenue of $1.2 million in Q3 2024, a 20% increase compared to the previous quarter[6] - EsoGuard test volume reached 2,787 in Q3 2024[6] - Over 7,000 firefighters have undergone EsoGuard esophageal precancer testing[6] - Year-to-date revenue for 3Q24 reached $3.149 million, a $1.761 million increase compared to $1.388 million in 3Q23[34] Strategic Accomplishments - The ESOGUARD BE-1 clinical validation study was accepted for peer-reviewed publication[8] - A key patent underlying EsoGuard received a Notice of Allowance[8] - Lucid Diagnostics met with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's Molecular Diagnostics Program (MolDX) to discuss EsoGuard clinical evidence package for upcoming submission for Medicare coverage[8] Financials - Cash reserves decreased from $24.920 million in 2Q24 to $14.489 million in 3Q24, a decrease of $10.431 million[32] - Net loss for 3Q24 was $(12.371) million, compared to $(14.208) million in 3Q23, an improvement of $1.837 million[34] - Non-GAAP adjusted loss per share improved from $(0.22) in 3Q23 to $(0.20) in 3Q24[34] - Shares outstanding increased from 49.3 million in 2Q24 to 51.6 million in 3Q24, an increase of 2.3 million shares[32]

Core Insights - RadNet, Inc. is a leading provider of outpatient diagnostic imaging services in the United States, operating a network of imaging centers that offer MRI, CT, and PET scans [1] - The company is set to release its quarterly earnings on November 10, 2025, with analysts expecting an EPS of $0.23, reflecting a year-over-year increase of 27.8% [2] - Projected revenue for the upcoming quarter is approximately $494 million, with a slightly higher forecast of $498 million, marking an 8% rise from the previous year [2] - The consensus EPS estimate has been revised upward by 3.7% over the past 30 days, indicating positive reevaluation by analysts [3] Financial Metrics - RadNet has a price-to-sales ratio of approximately 3.18 and an enterprise value to sales ratio of about 3.71, reflecting the market's valuation of its revenue [4] - The company's debt-to-equity ratio is approximately 1.97, indicating nearly twice as much debt as equity [5] - A current ratio of about 2.00 suggests that RadNet has twice as many current assets as current liabilities, indicating positive short-term financial health [5]

Core Insights - Quest Diagnostics will present its strategy, performance, and market trends at Citi's 2025 Global Healthcare Conference on December 2, 2025 [1] - The presentation will include a live webcast and an archived version available for 24 hours post-event [2] Company Overview - Quest Diagnostics is a leader in diagnostic information services, providing insights from laboratory testing to improve health outcomes [3] - The company serves one in three adult Americans and half of the physicians and hospitals in the U.S., employing over 55,000 individuals [3]

Core Insights - The Quest AD-Detect® blood tests demonstrate high accuracy in identifying Alzheimer's disease pathology, potentially reducing the need for PET imaging confirmation [1][2][3] Test Performance - The study evaluated two blood tests with 91% sensitivity and 91% specificity in a population of 215 patients with mild cognitive impairment or Alzheimer's disease, where 46% were amyloid PET-positive [4][5] - The test combining AB 42/40, p-tau217, and ApoE4 had a positive predictive value (PPV) of 88% and a negative predictive value (NPV) of 91%, while the test without ApoE4 had a PPV of 87% and the same NPV [4] Indeterminate Results - The indeterminate rate was found to be 10% for the test with all three biomarkers and 15% for the test without ApoE4, aligning with recommendations that no more than 15%-20% of individuals should have indeterminate results [5] Market Context - Nearly 7 million Americans are diagnosed with Alzheimer's disease, projected to reach 14 million by 2060, highlighting the growing need for effective diagnostic tools [7] - Blood tests are considered more cost-effective compared to invasive methods like CSF lumbar puncture and PET imaging, which could benefit the healthcare system [8] Company Commitment - Quest Diagnostics is focused on developing innovative diagnostics for Alzheimer's disease and other brain diseases, aiming to improve patient care and health outcomes [8][9]

Core Insights - Quest Diagnostics reported a strong financial performance for Q3 2025, with revenues increasing by 13.1% year-over-year, driven by organic growth of 6.8% and contributions from acquisitions [2][6] - The company has raised its full-year 2025 guidance due to robust year-to-date performance [2][5] Financial Performance - Q3 2025 net revenues reached $2.82 billion, up from $2.49 billion in Q3 2024, marking a 13.1% increase [4] - Diagnostic Information Services revenues were $2.76 billion, a 13.5% increase from $2.43 billion in the previous year [4] - Operating income for Q3 2025 was $386 million, an increase of 16.8% compared to $330 million in Q3 2024 [4] - Net income attributable to Quest Diagnostics was $245 million, up 8.5% from $226 million in Q3 2024 [4] - Diluted EPS for Q3 2025 was $2.16, reflecting an 8.5% increase from $1.99 in Q3 2024 [4] Year-to-Date Performance - Year-to-date cash provided by operations was $1.42 billion, a significant increase of 63.1% from $870 million in the same period last year [6] - For the first nine months of 2025, net revenues totaled $8.23 billion, up 13.5% from $7.25 billion in 2024 [4] Updated Guidance - The updated guidance for full-year 2025 includes net revenues projected between $10.96 billion and $11.00 billion, an increase from the previous range of $10.80 billion to $10.92 billion [5] - Reported diluted EPS is now expected to be between $8.58 and $8.66, while adjusted diluted EPS is projected to be between $9.76 and $9.84 [5][6] Strategic Developments - Quest Diagnostics entered into a joint venture with Corewell Health to provide lab services in Michigan, with expected annual revenues for Co-Lab Solutions reaching approximately $1 billion [2][7] - The company completed the acquisition of dialysis testing assets from Fresenius Medical Care, enhancing its clinical lab testing capabilities [7] - Collaborations with WHOOP and URA Health aim to integrate Quest's services into wellness and preventive health applications [7]

Core Points - Biodesix, Inc. will release its financial results for Q3 2025 on November 3, 2025, after market close [1] - A conference call and webcast will be held at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update [1] - Registration links for the webcast and Q&A session are available for analysts and listeners [2] Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients [3] - The company offers diagnostic tests such as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, which aid in clinical decision-making for lung disease [3] - Biodesix Development Services support biopharmaceutical and life sciences institutions in developing diagnostic tests and therapeutics [3]